IRLA

SEC source: 0001209191-23-016507 · doc4.xml · nonDerivative · entry 1

Monohon Ted · CIK 0001606905 · Chief Accounting Officer & VP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,440

F1 · shares: Represents shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 4,250 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022.

SEC source: 0001209191-23-006402 · doc4.xml · derivative · entry 1

Thye Dirk · CIK 0001638945 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 600,000

Underlying: Common Stock · 600,000 shares

Expires 2033-01-31

F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date.

SEC source: 0001209191-23-006398 · doc4.xml · derivative · entry 1

Monohon Ted · CIK 0001606905 · Chief Accounting Officer & VP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 110,000 shares

Expires 2033-01-31

F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date.

SEC source: 0001209191-23-006401 · doc4.xml · derivative · entry 1

Smith Karen L. · CIK 0001639637 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Common Stock · 225,000 shares

Expires 2033-01-31

F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date.

SEC source: 0001209191-23-006394 · doc4.xml · derivative · entry 1

Hannah Brendan · CIK 0001929422 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Common Stock · 225,000 shares

Expires 2033-01-31

F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date.

SEC source: 0001209191-22-060218 · doc4.xml · nonDerivative · entry 1

Monohon Ted · CIK 0001606905 · Chief Accounting Officer & VP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,311

F1 · shares: Represents shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 4,250 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022.

SEC source: 0001209191-22-049221 · doc4.xml · nonDerivative · entry 1

Monohon Ted · CIK 0001606905 · Chief Accounting Officer & VP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,951

F1 · shares: Represents shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 4,250 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022.

SEC source: 0001209191-22-040306 · doc4.xml · derivative · entry 1

Monohon Ted · CIK 0001606905 · Chief Accounting Officer & VP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2032-06-28

F1 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments from the vesting commencement date.

SEC source: 0001209191-22-035877 · doc4.xml · derivative · entry 1

Bray June · CIK 0001845487 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,000

Underlying: Common Stock · 54,000 shares

Expires 2032-06-08

F1 · derivative.exercise_date: The shares subject to the stock option shall vest in equal annual installments over the three-year period following the grant date of June 9, 2022.

SEC source: 0001209191-22-035674 · doc4.xml · derivative · entry 1

RYAN UNA S · CIK 0001255349 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2032-06-07

F1 · derivative.exercise_date: 100% of the shares subject to the stock option shall vest in full on the one-year anniversary of the grant date of June 8, 2022.

SEC source: 0001209191-22-035678 · doc4.xml · derivative · entry 1

Senner Christopher J. · CIK 0001648367 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2032-06-07

F1 · derivative.exercise_date: 100% of the shares subject to the stock option shall vest in full on the one-year anniversary of the grant date of June 8, 2022.

SEC source: 0001209191-22-035672 · doc4.xml · derivative · entry 1

Lamond David · CIK 0001770790 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2032-06-07

F1 · derivative.exercise_date: 100% of the shares subject to the stock option shall vest in full on the one-year anniversary of the grant date of June 8, 2022.

SEC source: 0001209191-22-035671 · doc4.xml · derivative · entry 1

McLoughlin Margaret · CIK 0001770823 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2032-06-07

F1 · derivative.exercise_date: 100% of the shares subject to the stock option shall vest in full on the one-year anniversary of the grant date of June 8, 2022.

SEC source: 0001209191-22-035014 · doc4.xml · nonDerivative · entry 2

McDowell Caryn Gordon · CIK 0001674232 · Chief Legal & Adm. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,500

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.78 to $3.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001209191-22-035014 · doc4.xml · nonDerivative · entry 1

McDowell Caryn Gordon · CIK 0001674232 · Chief Legal & Adm. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,300

F1 · shares: Represent shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 17,500 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.78 to $3.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001209191-22-035020 · doc4.xml · nonDerivative · entry 1

Monohon Ted · CIK 0001606905 · Chief Accounting Officer & VP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,471

F1 · shares: Represent shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 4,250 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022.

SEC source: 0001209191-22-035017 · doc4.xml · nonDerivative · entry 1

Holsinger Leslie · CIK 0001770821 · EVP, Preclinical Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,080

F1 · shares: Represent shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 19,437 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.78 to $3.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001209191-22-031515 · doc4.xml · derivative · entry 3

Thye Dirk · CIK 0001638945 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,979,650

Underlying: Common Stock · 1,979,650 shares

Expires 2032-05-22

F2 · derivative.exercise_date: The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years.

SEC source: 0001209191-22-031508 · doc4.xml · derivative · entry 3

Smith Karen L. · CIK 0001639637 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,365,449

Underlying: Common Stock · 1,365,449 shares

Expires 2032-05-22

F2 · derivative.exercise_date: The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years.

SEC source: 0001209191-22-031498 · doc4.xml · derivative · entry 3

Hannah Brendan · CIK 0001929422 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 353,656

Underlying: Common Stock · 353,656 shares

Expires 2032-05-22

F2 · derivative.exercise_date: The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years.

SEC source: 0001209191-22-031515 · doc4.xml · derivative · entry 2

Thye Dirk · CIK 0001638945 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 206,391

Underlying: Common Stock · 206,391 shares

Expires 2022-03-27

F3 · price: Received in the Merger in exchange for an employee stock option to acquire 2,266,500 shares of Novosteo common stock for $0.05 per share.

F2 · derivative.exercise_date: The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years.

SEC source: 0001209191-22-031515 · doc4.xml · nonDerivative · entry 1

Thye Dirk · CIK 0001638945 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,589

F1 · price: On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer.

SEC source: 0001209191-22-031503 · doc4.xml · derivative · entry 3

Low Philip S · CIK 0001509669 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,058

Underlying: Common Stock · 22,058 shares

Expires 2032-05-18

F2 · derivative.exercise_date: The shares subject to the option shall vest in equal annual installments over the three-year period following the grant date of May 19, 2022.

SEC source: 0001209191-22-031503 · doc4.xml · nonDerivative · entry 2

Low Philip S · CIK 0001509669 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Philip S. Low Revocable Trust

Disclosed balance after: 63,974

F1 · price: On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer.

SEC source: 0001209191-22-031503 · doc4.xml · nonDerivative · entry 1

Low Philip S · CIK 0001509669 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 455,309

F1 · price: On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer.

SEC source: 0001209191-22-031508 · doc4.xml · derivative · entry 2

Smith Karen L. · CIK 0001639637 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,799

Underlying: Common Stock · 151,799 shares

Expires 2032-03-27

F3 · price: Received in the Merger in exchange for an employee stock option to acquire 1,667,000 shares of Novosteo common stock for $0.05 per share.

F2 · derivative.exercise_date: The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years.

SEC source: 0001209191-22-031508 · doc4.xml · nonDerivative · entry 1

Smith Karen L. · CIK 0001639637 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,336

F1 · price: On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer.

SEC source: 0001209191-22-031500 · doc4.xml · nonDerivative · entry 1

Lamond David · CIK 0001770790 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By David A. Lamond Trust dated 2006

Disclosed balance after: 1,734,722

F1 · price: On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer.

F2 · ownership.nature: Mr. Lamond is the trustee of David A. Lamond Trust dated 2006 (the "2006 Trust") and holds sole voting and dispositive power with respect to the shares held of record by the 2006 Trust.

SEC source: 0001209191-22-031498 · doc4.xml · derivative · entry 2

Hannah Brendan · CIK 0001929422 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,500

Underlying: Common Stock · 103,500 shares

Expires 2032-03-27

F3 · price: Received in the Merger in exchange for an employee stock option to acquire 1,136,600 shares of Novosteo common stock for $0.05 per share.

F2 · derivative.exercise_date: The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years.

SEC source: 0001209191-22-031498 · doc4.xml · nonDerivative · entry 1

Hannah Brendan · CIK 0001929422 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,224

F1 · price: On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer.

SEC source: 0001209191-22-032675 · doc4a.xml · nonDerivative · entry 1

Thye Dirk · CIK 0001638945 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,911

F1 · shares: The shares vest monthly, subject to continued service.

F2 · price: On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer.

SEC source: 0001209191-22-032677 · doc4a.xml · nonDerivative · entry 1

Smith Karen L. · CIK 0001639637 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 194,690

F1 · shares: The shares vest monthly, subject to continued service.

F2 · price: On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer.

SEC source: 0001209191-22-032672 · doc4a.xml · nonDerivative · entry 1

Hannah Brendan · CIK 0001929422 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,793

F1 · shares: The shares vest monthly, subject to continued service.

F2 · price: On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer.

SEC source: 0001209191-22-019311 · doc4.xml · derivative · entry 1

Sabbagh Marwan · CIK 0001917672 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,058

Underlying: Common Stock · 22,058 shares

Expires 2032-03-13

F1 · derivative.exercise_date: The shares subject to the option shall vest in equal annual installments over the three-year period following the grant date of March 14, 2022.

SEC source: 0001209191-22-016441 · doc4.xml · nonDerivative · entry 1

McDowell Caryn Gordon · CIK 0001674232 · Chief Legal & Adm. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,000

F1 · shares: Represents grant of Restricted Stock Units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award shall vest in equal quarterly installments over two years, with 1/8th of the total number of shares subject to the RSU Award vesting on each quarterly anniversary of the date of grant.

SEC source: 0001209191-22-016440 · doc4.xml · nonDerivative · entry 1

LOWE CHRISTOPHER P. · CIK 0001376260 · Interim CEO, COO & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 265,000

F1 · shares: Represents grant of Restricted Stock Units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award shall vest in equal quarterly installments over two years, with 1/8th of the total number of shares subject to the RSU Award vesting on each quarterly anniversary of the date of grant.

SEC source: 0001209191-22-016443 · doc4.xml · nonDerivative · entry 1

Monohon Ted · CIK 0001606905 · Chief Accounting Officer & VP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,000

F1 · shares: Represents grant of Restricted Stock Units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award shall vest in equal quarterly installments over two years, with 1/8th of the total number of shares subject to the RSU Award vesting on each quarterly anniversary of the date of grant.

SEC source: 0001209191-22-016429 · doc4.xml · nonDerivative · entry 1

Holsinger Leslie · CIK 0001770821 · EVP, Preclinical Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,000

F1 · shares: Represents grant of Restricted Stock Units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award shall vest in equal quarterly installments over two years, with 1/8th of the total number of shares subject to the RSU Award vesting on each quarterly anniversary of the date of grant.

SEC source: 0001209191-22-016428 · doc4.xml · nonDerivative · entry 1

Detke Michael J. · CIK 0001770786 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,000

F1 · shares: Represents grant of Restricted Stock Units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award shall vest in equal quarterly installments over two years, with 1/8th of the total number of shares subject to the RSU Award vesting on each quarterly anniversary of the date of grant.

SEC source: 0001209191-22-001792 · doc4.xml · derivative · entry 1

McDowell Caryn Gordon · CIK 0001674232 · Chief Legal & Adm. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2032-01-02

F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the date of grant, such that the total number of shares shall be fully vested on the four-year anniversary of the date of grant.

SEC source: 0001209191-22-001788 · doc4.xml · derivative · entry 1

LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2032-01-02

F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the date of grant, such that the total number of shares shall be fully vested on the four-year anniversary of the date of grant.

SEC source: 0001209191-22-001824 · doc4.xml · derivative · entry 1

Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 440,000

Underlying: Common Stock · 440,000 shares

Expires 2032-01-02

F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the date of grant, such that the total number of shares shall be fully vested on the four-year anniversary of the date of grant.

SEC source: 0001209191-22-001759 · doc4.xml · derivative · entry 1

Holsinger Leslie · CIK 0001770821 · EVP, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2032-01-02

F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the date of grant, such that the total number of shares shall be fully vested on the four-year anniversary of the date of grant.

SEC source: 0001209191-22-001754 · doc4.xml · derivative · entry 1

Dominy Stephen S. · CIK 0001770860 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2032-01-02

F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the date of grant, such that the total number of shares shall be fully vested on the four-year anniversary of the date of grant.

SEC source: 0001209191-22-001752 · doc4.xml · derivative · entry 1

Detke Michael J. · CIK 0001770786 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2032-01-02

F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the date of grant, such that the total number of shares shall be fully vested on the four-year anniversary of the date of grant.

SEC source: 0001209191-22-001731 · doc4.xml · derivative · entry 1

Monohon Ted · CIK 0001606905 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2031-12-13

F1 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments from the vesting commencement date.

SEC source: 0001209191-21-065993 · doc4.xml · derivative · entry 4

Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,159

Underlying: Common Stock · 60,000 shares

Expires 2027-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested as to 1/48th of the shares on July 13, 2017, and the remaining shares vested in equal monthly installments from August 13, 2017 and ended on June 13, 2021.

F4 · derivative.expiration_date: The expiration date of this option was erroneously reported as 06/0/1/2022 on the Form 3 filed on May 8, 2019.

SEC source: 0001209191-21-065993 · doc4.xml · nonDerivative · entry 1

Lynch Casey · CIK 0001770783 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,895

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-064924 · doc4.xml · derivative · entry 2

LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,294

Underlying: Common Stock · 30,000 shares

Expires 2028-11-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option will vest as to 25% of the shares on November 15, 2019, with the remaining 75% of shares vesting in equal monthly installments beginning on December 15, 2019 and ending on November 15, 2022.

SEC source: 0001209191-21-064924 · doc4.xml · nonDerivative · entry 1

LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.